Table 3.

Correlations between DTI measures, ALS disease stage, and clinical scores in 28 C9+ subjects, observations from all visits

	King’s disease stage†	ALSFRS-R	Letter Fluency	FBI
Number of observations	61	61	59	59
R CST FA	−0.47	0.60	n.s.	n.s.
R CST MD	0.59	−0.64	n.s.	n.s.
L CST FA	−0.39	0.60	n.s.	n.s.
L CST MD	0.61	−0.56	n.s.	0.48
R UNC FA	n.s.	n.s.	n.s.	−0.51
R UNC MD	n.s.	n.s.	n.s.	0.81
L UNC FA	n.s.	n.s.	n.s.	n.s.
L UNC MD	n.s.	n.s.	n.s.	0.73
CCg FA	−0.26	n.s.	n.s.	−0.58
CCg MD	0.35	n.s.	n.s.	0.80
CCpm FA	−0.23	n.s.	n.s.	−0.58
CCpm MD	0.27	n.s.	n.s.	0.73
CCm FA	−0.54	0.60	n.s.	n.s.
CCm MD	0.48	n.s.	n.s.	0.61
CCsp FA	n.s.	n.s.	n.s.	n.s.
CCsp MD	0.40	n.s.	n.s.	n.s.

^*Spearman’s rho; all other columns show Pearson’s r. All correlations shown were signi cant at threshold p<0.05. Correlations with |r|>0.5 are shown in bold.

ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS Functional Rating Scale; CCg, corpus callosum—genu; CCm, corpus callosum—motor; CCpm, corpus callosum—pre-motor; CCsp, corpus callosum—splenium; CST, corticospinal tract; DTI, diffusion tensor imaging; FA, fractional anisotropy; FBI, Frontal Behavioural Inventory; L, left; MD, mean diffusivity; n.s, not signi cant; R, right; UNC, uncinate fasciculus.